Artes Medical Announces JMP Securities Has Been Engaged to Lead Strategic Process
10 Novembre 2008 - 10:50PM
Business Wire
Artes Medical, Inc. (Nasdaq:ARTE), a medical technology company
whose product ArteFill� is the first and only FDA-approved
non-resorbable injectable dermal filler for the correction of
nasolabial fold or �smile line� wrinkles, reported that JMP
Securities, a leading Life Sciences investment bank, has been
engaged to assist the Company in exploring financing opportunities
and strategic opportunities on behalf of the Company and its Board
of Directors. The Company will also continue to pursue equity and
debt transactions to raise additional capital to fund its
operations. There can be no assurance that the exploration of
strategic alternatives will result in any agreements or
transactions, or that, if completed, any agreements or transactions
will be successful or on attractive terms. In order to be
considered by the Board, any strategic alternative or financing
transaction must be presented through a written term sheet, which
outlines the material terms and conditions of the proposed
transaction and sources of funding. In evaluating the terms of a
proposed transaction, the Board will focus on the timing of the
proposed transaction and closing certainty, including limited
closing conditions and financing contingencies. The�Company�does
not intend to disclose developments with respect to this process
unless and until the evaluation of strategic alternatives or a
financing transaction have been completed. About Artes Medical,
Inc. Artes Medical is a medical aesthetics company focused on
developing, manufacturing and commercializing a new category of
aesthetic injectable products for the dermatology and plastic
surgery markets. The Company's flagship product, ArteFill, is being
marketed to men and women as a treatment option for the correction
of nasolabial folds. Additional information about Artes Medical and
ArteFill is available at www.artesmedical.com and www.artefill.com.
Forward-Looking Statements This press release contains
forward-looking statements that are based on the Company's current
beliefs and assumptions and on information currently available to
its management and Board of Directors. Forward-looking statements
involve known and unknown risks, uncertainties and other factors
that may cause the Company's actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. As a result of these risks,
uncertainties and other factors, which include the Company's
history of net losses, its ability to timely raise additional funds
to support its operations and future product acquisition plans, its
ability to manage its operating expenses, its reliance on sales of
ArteFill and Elevess, its future receipt of FDA approval to extend
the efficacy period of ArteFill beyond six months and eliminate the
skin test requirement, and the risk that the Company's revenue
projections may prove incorrect because of unexpected difficulty in
generating sales and market acceptance of ArteFill and Elevess,
readers are cautioned not to place undue reliance on any
forward-looking statements included in this letter to stockholders.
A more extensive set of risks and uncertainties is set forth in the
Company's SEC filings available at www.sec.gov. These
forward-looking statements represent beliefs and assumptions only
as of the date of this press release, and the Company assumes no
obligation to update these forward-looking statements publicly,
even if new information becomes available in the future. Artes
Medical� and ArteFill� are registered trademarks of Artes Medical,
Inc. All other trademarks, trade names and brand names referred to
in this�press release are the property of their respective owners.
Grafico Azioni Artemis Strategic Invest... (NASDAQ:ARTE)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Artemis Strategic Invest... (NASDAQ:ARTE)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Artemis Strategic Investment Corporation (NASDAQ): 0 articoli recenti
Più Artes Medical, Inc. Articoli Notizie